EMEA-001813-PIP01-15
Key facts
Active substance |
Recombinant humanized anti-MMP9 monoclonal antibody IgG4 (GS-5745)
|
Therapeutic area |
Gastroentology-Hepatology
|
Decision number |
P/0146/2016
|
PIP number |
EMEA-001813-PIP01-15
|
Pharmaceutical form(s) |
Solution for injection
|
Condition(s) / indication(s) |
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Gilead Sciences International Ltd
E-mail: regulatory.pip@gilead.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|